Biotech News

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

C4 Therapeutics (CCCC)C4 TherapeuticsConference / presentation

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the 8 th Annual Evercore Healthcare Conference taking place from December 2 - 4, 2025 in Coral Gables, Florida.

Fireside Chat Details: Event: 8 th Annual Evercore Healthcare Conference Date/Time: Wednesday, December 3 rd , 2025 at 3:25 pm ET

A live webcast will be available on the Investors section of the company’s website at www.c4therapeutics.com . An archived replay of the webcast will be available for approximately 90 days following the live event.

About C4 Therapeutics

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO ® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:

Investors: Courtney Solberg Associate Director, Investor Relations [email protected]

Media: Loraine Spreen Senior Director, Corporate Communications & Patient Advocacy [email protected]

Related news

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

CCCCC4 Therapeutics2026-08-10 20:01 EST

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CCCCC4 Therapeutics2026-06-11 11:00 EST

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

C4 Therapeutics

Targeted Protein Degradation Company C4 Therapeutics develops medicines that use the cell’s protein-disposal machinery to remove disease-causing proteins. Cemsidomide Cemsidomide is an oral molecular glue degrader of IKZF1 and IKZF3 being developed as a potential foundational therapy for multiple myeloma. Combination Strategy Clinical...

Recent company news

Stock data

Close
4.00 USD
Market cap
479.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States